Diego Pellicer Worldwide, Inc. operates as a real estate and a consumer retail development company in the United States. The company acquires and develops legally compliant real estate locations for the purposes of leasing them to state licensed companies in the cannabis industry. It also offers non-cannabis infused products, apparel, and other tangible products in retail outlets. The company was founded in 2012 and is based in Los Angeles, California.
MCW Energy Group Limited, through its subsidiary, MCW Energy CA, Inc., engages in the oil sands extraction business in the United States. The company is involved in the tar sands mining and oil processing activities using a closed-loop solvent based extraction system that recovers bitumen from surface mining. It also holds interest in the MCW Mineral lease covering approximately 1,138 acres; and the TMC Mineral lease on the Asphalt Ridge property covering approximately 1128 acres located in Uintah County, Utah. The company was formerly known as MCW Enterprises Ltd. and changed its name to MCW Energy Group Limited in December 2012. MCW Energy Group Limited is headquartered in Los Angeles, California.
Immune Pharmaceuticals Inc. (NASDAQ: IMNP) applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer.
The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma.
The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells.
The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors.
Immune is headquartered in the U.S., with its primary research and development facilities in Israel.
Cellular Biomedicine Group Inc., a biomedicine company, develops treatments for cancerous and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat serious chronic and degenerative diseases, such as cancer, osteoarthritis, tissue damage, various inflammatory diseases, and metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; and tumor cell specific dendritic cell therapy. Cellular Biomedicine Group Inc. was incorporated in 2001 and is headquartered in Cupertino, California.
BIO-key is Revolutionizing Authentication, as our easy to use biometric solutions enable convenient and secure access to information and financial transactions. We eliminate passwords, PINs tokens and cards and make it easy for enterprises and consumers to secure their devices as well as information in the cloud. Our premium finger scanning devices SideSwipe and EcoID offer market leading quality, performance and price. Now anyone can BIO-key their world!
OncoSec Medical Incorporated, a biotechnology company, designs, develops, and commercializes gene therapies, and therapeutics and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer in the United States. Its lead program, ImmunoPulse IL-12, is in Phase II development for various indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. ImmunoPulse is an electroporation delivery device used in combination with the companys therapeutic product candidates, including DNA plasmids that encode for immunologically active agents, and to deliver the therapeutic directly into the tumor and promote an inflammatory response against the cancer.
Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostics and therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, and ophthalmological disorders. The companys diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimers disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with relapsing-remitting multiple sclerosis at first clinical presentation.
Its therapeutic products in development comprise Eltoprazine, a small molecule drug that is in Phase II clinical trials for the treatment of Parkinsons disease Levadopa-Induced Dyskinesia and adult attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including iretinitis pigmentosa, Parkinsons disease, cardiac ischemia, and stroke. It is also developing NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinsons disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery.
Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University to develop its full thickness skin replacement product. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus Bioscience Holdings, Inc. in April 2013. Amarantus Bioscience Holdings, Inc. was founded in 2008 and is based in San Francisco, California.